TrialsgrambetaRCTs are beautiful
AHA Scientific Sessions 2026Apresentado seg., 9 de nov. · 08:00 GMT-6LBS.05 Late-breaking Science: New Frontiers in Cardiometabolic Risk ReductionTodos os ensaios Late-Breaking Science →

TYDAL-TIMI 78

2026

TYDAL-TIMI 78: Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of MAR001 in Patients With Elevated Triglycerides and Remnant Cholesterol

In adults with elevated triglyceride and remnant cholesterol levels, ANGPTL4 inhibition with MAR001 reduced fasting triglyceride levels at 12 weeks compared with placebo.

Resultado

Desfecho primário: Primary endpoint at 12 weeks (the registration does not name the measure)

At week 12, in an intention-to-treat analysis, the placebo-adjusted least-squares mean percent changes in the fasting triglyceride level with the three MAR001 doses were -39.1 percentage points, -40.5 percentage points and -45.3 percentage points (P<0.001 for all comparisons). Adverse events occurred in 123 of 177 participants (69%) in the pooled MAR001 group vs 45 of 58 participants (78%) in the placebo group.

Publicação original
Subtema
Triglycerides
Desenho
Phase 2b, double-blind, placebo-controlled, dose-ranging trial (Marea Therapeutics; TIMI Study Group; 55 sites in the US, Canada, Australia and New Zealand) of subcutaneous MAR001, an ANGPTL4 inhibitor, in two parts with four dose arms
Incluídos
236 doentes
Fonte
O'Donoghue ML, Juliano RA, et al. N Engl J Med. 2026; published online 9 November.doi 10.1056/NEJMoa2612463

Discussão e crítica

All three doses of MAR001 lowered fasting triglyceride levels compared with placebo at 12 weeks in part A of this phase 2b trial. Triglyceride level is a surrogate, and treatment lasted only 24 weeks, so the trial cannot show any effect on clinical events or long-term safety. The abstract does not report confidence intervals, remnant cholesterol results or glycaemic measures, and part B is not part of this report. The trial was funded by Marea Therapeutics.